73 results about "Fibronectin" patented technology

The invention belongs to the technical field of medicines, and particularly relates to application of sophora alcohol T in preparation of an anti-hepatic fibrosis medicine. The invention provides the application of the sophora alcohol T in preparation of the anti-hepatic fibrosis medicine for the first time, for example, the sophora alcohol T can be applied to preparation of the medicine for preventing or treating hepatic fibrosis. The compound can be used for preparing medicines for inhibiting hepatic stellate cell proliferation or activation, inhibiting fibronectin level rise, inhibiting alpha-smooth muscle actin level rise or inhibiting I-type collagen level rise, and has good patent medicine potential and wide development, transformation and clinical application value and prospect, and the compound can be used for preparing medicines for inhibiting hepatic stellate cell proliferation or activation, inhibiting fibronectin level rise, inhibiting alpha-smooth muscle actin level rise or inhibiting I-type collagen level rise.

The invention belongs to the technical field of medicines, and particularly discloses application of fibronectin 1 (FN1) in treatment of mycobacterial infection. The invention finds that the FN1 has new application, and the survival of mycobacteria can be inhibited when the FN1 is independently applied; in a mycobacterium infection model, after the FN1 protein is exogenously added, the number of mycobacteria in macrophages is remarkably reduced; on the contrary, after the FN1 is knocked down, the number of mycobacteria in the macrophage is obviously increased. Further mechanism research shows that the FN1 affects release of reactive oxygen species (ROS) and cytokines by regulating a PI3K / AKT signaling pathway, and further removes mycobacteria in macrophages. From the perspective of host immunity, the invention discloses a mechanism that FN1 affects ROS (reactive oxygen species) and inflammatory response by regulating a PI3K / AKT signal channel so as to inhibit mycobacteria, and a new medicine is provided for treatment of mycobacteria infection. On the basis, FN1 can be independently used or combined with first-line antituberculosis drugs, and a new means is provided for solving the problem of drug resistance in mycobacterium infection treatment.

A method for the expression and / or for the amplification of the expression of thrombospondin-1, fibronectin, vimentin and / or mimecan in human skin. the method comprises applying to human skin at least one caviar extract which is capable of causing the expression and / or the amplification of the expression of thrombospondin-1, fibronectin, vimentin and / or mimecan in human skin.

A universal biological prosthesis of acellular dermal matrix (ADM) intended for use in body reconstruction processes and method of manufacture. A universal biological prosthesis of acellular dermal matrix (ADM) intended for use in body reconstruction processes, comprising: a first layer of ADM of biological origin arranged inferiorly to delimit a cavity with a lower edge; a filling material disposed in the cavity surrounded by the first layer of ADM consisting of a ground ADM having the consistency of a fibrous paste; and a second layer of ADM of biological origin arranged on the upper part covering the filling material and whose upper edge rests peripherally on the lower edge of the first layer of ADM, thus defining a rim;where the first layer of ADM and the second layer of ADM are joined by an eyebrow overlap along the upper edge of the first layer of ADM with the lower edge of the peripheral rim using a biocompatible adhesive, or by absorbable suture; where the first layer of ADM, the second layer of ADM and the ADM filling material are not immunogenic; and where the ADM comprises collagen fibers, fibronectin, elastin, laminin, glycosaminoglycans and hyaluronic acid. Method for its manufacture.

The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.

According to the RNA binding protein HuR inhibitor and the anti-fibrosis application thereof, the compound provided by the invention has obvious inhibitory activity on HuR protein, has a good anti-renal fibrosis effect, can obviously reduce protein and mRNA expression levels of fibronectin (FN1) and alpha-smooth muscle actin (alpha-SMA), can improve renal function impairment, and can be used for preparing the anti-fibrosis medicine for treating renal fibrosis. The levels of blood urea nitrogen (BUN) and creatinine (Cr) which are commonly used for evaluating the renal function are reduced, and the compound can be used for preparing the medicine for treating the chronic kidney disease.

Provided herein are methods of preparing modified fibronectin proteins. Also provided herein are methods of preparing such modified fibronectin proteins and their use in connection with purifying components of interest. Also provided herein are methods of preventing filter fouling using cell lines engineered to express the modified fibronectin proteins described herein.

The invention relates to the technical field of artificial dermis, in particular to a preparation method and application of artificial dermis based on bionic acellular matrix. The artificial dermis comprises a bionic acellular matrix component A and an auxiliary material component B, wherein the component A comprises type I collagen, type VI collagen, elastin, fibronectin, laminin, mother cell protein and glucan; the component B comprises antibacterial peptide, antibiotics and a high-molecular polymer material; the mass ratio of the component A to the component B is (4-6): (1-4). The preparation method comprises the following steps: respectively preparing procedure mother liquor of the component A and the component B, preparing hydrogel with a double-layer gradient structure through step-by-step crosslinking, and then carrying out freeze drying and sterilization treatment. The artificial dermis disclosed by the invention has good biocompatibility and antibacterial property, can effectively promote wound healing, is suitable for repairing acute and chronic wounds of four limbs, faces and trunk parts, and is particularly suitable for repairing complex wounds with exposed bones, tendons, nerves and blood vessels.

This invention provides a liquid crystal biomimetic water-locking and oxygen-permeable skincare composition, its preparation method, and its application, belonging to the field of cosmetic technology. It comprises the following components by weight percentage: 20-40% glycerin, 5-10% hydrogenated lecithin, 5-10% phytosterols, 0.1-0.5% sodium stearoyl glutamate, 0.01-0.05% sodium methylstearoyl taurate, 0.1-1% ceramide NP, 1-10% caprylic / capric triglyceride, 1-10% squalane, 0.1-1% tocopheryl acetate, 0.01-0.3% sodium DNA, 0.001-0.1% fibronectin, 0.001-0.1% soluble collagen, and the balance being water. The liquid crystal biomimetic water-locking and oxygen-permeable skincare composition provided by this invention can better form a breathable protective film on the skin surface, reduce skin moisture loss, and help repair damaged skin barriers, thereby achieving the effect of water-locking and oxygen-permeable skincare.

The invention discloses a serum protein marker combination for detecting cerebral microhemorrhage, and belongs to the field of biological medicine detection.The serum protein marker combination comprises four serum proteins including matrix metalloproteinase 3, fibronectin-like extracellular matrix protein 1 containing epidermal growth factors, a metalloproteinase inhibiting factor 1 and uromodulin; through efficient and accurate serum protein marker combination, the defects that brain function magnetic resonance SWI examination is high in cost and long in time consumption, operation depends on high-level imaging physicians and the like are overcome, an innovative tool is provided for rapid, accurate and non-invasive screening and auxiliary diagnosis of cerebral microhemorrhage, and wide clinical application prospects are achieved.

The invention provides a compound fermentation polypeptide composition with whitening, anti-aging, moisturizing and repairing functions and application thereof, and belongs to the technical field of skin care products. The composite fermentation polypeptide composition comprises the following components: a micrococcus lysate, crithmum maritimum callus culture filtrate, a bifidobacterium fermentation product filtrate, a galactose yeast-like bacterium fermentation product filtrate, a tuber melanosporum extract, a peony root extract, acetyl hexapeptide-8, nonapeptide-1, hexapeptide-9, tetrahydromethylpyrimidine carboxylic acid, fibronectin and the like. The composite fermented polypeptide composition not only realizes multi-dimensional mildness and aging resistance, but also has the characteristics of brightening skin, enhancing skin barrier and the like, and is suitable for the field of skin care products.

The invention provides a composition and application thereof in promoting wound healing and reducing scar formation. The composition comprises 10 < 4 >-10 < 9 > particles / mL of exosomes and 5-1000 [mu] g / mL of fibronectin. Through collaborative design of the exosome and fibronectin, multi-mode regulation of promoting repair, controlling inflammation, regulating matrix and reducing scars on wound healing is realized, and the exosome has the advantages of comprehensive action mechanism, stable treatment effect and wide application range; the obvious application value and clinical transformation potential are realized in the fields of chronic wound repair, scar prevention and treatment and skin regeneration.

The present invention provides anti-human LILRB4 monoclonal antibodies or fragments thereof, immune checkpoint inhibitors, therapeutic agents for immune checkpoint-related diseases, and methods for measuring human LILRB4.SOLUTION: Anti-human immunosuppressive receptor LILRB4 monoclonal antibodies or fragments thereof that specifically bind to a human immunosuppressive receptor LILRB4 and inhibit binding between fibronectin and the human immunosuppressive receptor LILRB4, immune checkpoint inhibitors containing the anti-human immunosuppressive receptor LILRB4 monoclonal antibodies or fragments thereof as active ingredients, therapeutic agents for immune checkpoint-related diseases, and methods for measuring a human immunosuppressive receptor LILRB4 in a biological sample using the anti-human immunosuppressive receptor LILRB4 monoclonal antibodies or fragments thereof.SELECTED DRAWING: None

The invention discloses a fibroblast composite bone filling preparation as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The method comprises the following steps: specifically culturing fibroblasts by using Yoda1 and matrix I-type collagen, and activating the osteogenic differentiation capability of the fibroblasts; resuspending the finished product fibroblasts capable of activating the osteogenic differentiation capacity in a solution containing ginsenoside, tacrolimus and fibronectin to obtain a mixed solution; and finally, mixing the mixed solution with the bone filler to obtain the fibroblast composite bone filling preparation capable of promoting repair. The preparation can provide fibrosis support and promote vertebra fusion, does not cause inflammatory reaction, and has a large-scale application prospect.

The invention provides a serum-free medium for maintaining dryness of mesenchymal stem cells as well as a preparation method and application of the serum-free medium, and belongs to the technical field of biological medicines. The serum-free culture medium comprises a basic culture medium and an exogenous additive component, the basic culture medium is a DMEM / F12 culture medium, and the exogenous additive components comprise bFGF, EGF, PDGF-BB, recombinant human fibronectin, laminin, insulin, transferrin, sodium selenate, beta-mercaptoethanol and ascorbic acid. The serum-free culture medium provided by the invention is a special culture medium for the mesenchymal stem cells, which is completely free of animal-derived components, is suitable for large-scale amplification of clinical-grade cell treatment products, is relatively low in preparation cost and high in stem differentiation capability, and can remarkably improve the proliferation efficiency of the cultured mesenchymal stem cells.

The present application relates to the technical field of artificial dermis, and particularly relates to a preparation method and application of artificial dermis based on biomimetic acellular matrix. The artificial dermis comprises a biomimetic acellular matrix component A and an auxiliary component B, wherein the component A comprises type I collagen, type VI collagen, elastin, fibronectin, laminin, matricellular protein and dextran; the component B comprises antibacterial peptide, antibiotic and high molecular polymer material; the mass ratio of the component A to the component B is (4-6):(1-4). The preparation method comprises the steps of respectively preparing A and B component process mother liquor, step-by-step crosslinking to prepare a hydrogel with a double-layer gradient structure, and then freeze-drying and sterilization treatment. The artificial dermis has good biocompatibility and antibacterial performance, can effectively promote wound healing, and is suitable for repairing acute and chronic wounds of limbs, facial parts and trunk parts, and is particularly suitable for repairing complex wounds with exposed bones, tendons, nerves and blood vessels.

The invention belongs to the technical field of herbaceous plant extraction, and particularly relates to a collateral-dredging health-care gel extracted from herbaceous plants and a preparation process of the collateral-dredging health-care gel. The herbaceous plant raw materials are specifically prepared from coptis chinensis, radix sophorae flavescentis, pseudo-ginseng, dragon's blood, radix angelicae, lithospermum erythrorhizon, herba violae, fructus cnidii, cortex dictamni, fructus kochiae, angelica sinensis, turmeric, rhodiola rosea, selfheal, radix ranunculi ternati, pepper, rhizoma atractylodis, chamomile, smoked plum, saussurea involucrata, liquorice and water; the matrix is specifically prepared from carbomer, propylene glycol, glycerol, triethanolamine, nicotinamide, sodium polyglutamate, phenoxyethanol, fibronectin, sodium hyaluronate and purified water. Through combination of various herbaceous plant extracts and modern skin care components, the traditional Chinese medicine composition aims to regulate qi and blood in the body and promote blood circulation in an external use manner, and has a remarkable health care effect. The preparation process is scientific and reasonable, the curative effect of herbaceous plants is fully exerted, and meanwhile, the stability and safety of the product are ensured.

The invention relates to a dextran-fibronectin nanogel loaded with quercetin as well as preparation and application of the dextran-fibronectin nanogel, the dextran-fibronectin nanogel is prepared from the following components: the quercetin and the dextran-fibronectin nanogel, and the quercetin is wrapped by the dextran-fibronectin nanogel. The method is wide in raw material source, simple in preparation process, mild in condition and easy to operate and amplify. The drug-loaded nanogel provided by the invention can effectively penetrate through a damaged blood brain barrier in a Parkinson's disease mouse model, realizes intracerebral synergistic drug delivery, and has a good application prospect in treatment of neurodegenerative diseases.

The invention belongs to the technical field of gene engineering, and discloses recombinant human fibronectin as well as a preparation method and application thereof. The amino acid sequence of the recombinant human fibronectin disclosed by the invention is as shown in SEQ ID NO. 1. The recombinant human fibronectin comprises three fragments which are derived from natural fibronectin and have high hydrophilicity and multiple integrin binding capacity, the fragments are expressed in escherichia coli, and the recombinant human fibronectin with high soluble expression quantity is obtained; the recombinant human fibronectin has high activity of promoting proliferation and migration of human keratinocytes, and has potential application prospects in the aspects of skin repair and wound healing.

The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.

The invention belongs to the technical field of application of biomarker detection kits, and particularly relates to application of a kit for detecting fibronectin in evaluating the intestinal injury state, and the kit comprises an antibody specifically binding to fibronectin; the kit is used for detecting the fibronectin content in an excrement sample, and the intestinal injury state is evaluated based on the fibronectin content. In conclusion, the invention provides the application of the kit for detecting fibronectin, which is based on the excrement sample, is accurate in early stage and is superior to the existing marker, in evaluating the intestinal injury state.

Compositions and methods use one or more feline circulating proteins as markers for early chronic kidney disease (CKD) to diagnose and / or treat CKD. A method of diagnosing chronic kidney disease (CKD) in a feline can include measuring an amount of each of at least one circulating protein from the feline. The at least one circulating protein is one or more of adiponectin (ADIPOQ), antibacterial peptide (CAMP), kinetin-like protein (KIF12), plasma retinol binding protein (RBP4), Ig-like domain containing protein (ZKSCAN1), blood coagulation factor X (F10), fibronectin (FN1), and mixtures thereof. The method further comprises comparing the amount of each of the at least one circulating protein from the feline to a respective predetermined value or a respective predetermined range. The method further comprises diagnosing the feline as having or not having early CKD based on the comparison.

The application relates to the field of biomaterials and regenerative medicine, in particular to a preparation method and application of fibronectin and collagen protein-loaded PLGA nanoparticles, wherein the preparation method adopts a complex emulsion solvent evaporation method, a buffer solution containing fibronectin, collagen protein and trehalose is used as an inner water phase, a dichloromethane solution of PLGA is used as an oil phase, and a polyvinyl alcohol and trehalose-containing aqueous solution is used as an outer water phase; and the nanoparticles are prepared through emulsification, high-pressure homogenization, dialysis and freeze-drying. The method has the beneficial effects of stable process and effective protection of protein activity. The obtained nanoparticles have uniform particle sizes (100-200 nm), and can realize synergistic controllable release of double proteins. The product organically combines the physical filling support function of PLGA and the biological repair function of active factors, realizes the integration of "filling-regeneration", can significantly reduce the risk of inflammation, and can be safely applied to soft tissue filling, wrinkle improvement and skin wound repair in the field of medical cosmetology.

Mesothelin-binding theranostic fibronectin type III (Fn3) domain polypeptides conjugated to DOTAGA are described.

The invention discloses a gene modified fibroblast as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. Researches find that fibroblasts modified by the TIMP1 gene can stably secrete TIMP1 protein, the TIMP1 can promote the fibroblasts to secrete COL1A1 and Fibronectin, and the COL1A1 and the Fibronectin cooperate with each other to play a role in inhibiting growth of vascular endothelial cells, so that ingrowth of blood vessels in the intervertebral disc degeneration process is inhibited. And pathological angiogenesis in the degenerated intervertebral disc can be inhibited in a long-acting and targeted manner, so that the degeneration of the intervertebral disc is delayed.

This invention belongs to the field of cosmetic technology, specifically disclosing a multi-protein synergistic firming, anti-wrinkle, soothing, and repairing cosmetic composition, its preparation method, and its application. The cosmetic composition, by weight, is prepared from the following raw materials: 0.001-0.1 parts of Ma Yinglong Babao raw powder, 0.01-5 parts of oat firming protein, 0.01-1 part of silk protein, 0.001-0.1 parts of recombinant collagen, 0.001-0.1 parts of recombinant fibronectin, and 0.0001-0.1 parts of recombinant mussel protein. This invention utilizes the precise combination of oat firming protein, silk protein, recombinant collagen, recombinant fibronectin, recombinant mussel protein, and Ma Yinglong Babao raw powder to construct a four-in-one efficacy system of "firming-anti-wrinkle-soothing-repairing," achieving synergistic effects among the proteins. This solves the problems of existing products having single efficacy, poor synergy, and easy skin irritation, providing a highly effective and gentle comprehensive care solution for aging skin, sensitive skin, and skin with damaged skin barriers.

This invention provides a cosmetic composition with anti-wrinkle and repairing effects, its preparation method, and its application. The cosmetic composition with anti-wrinkle and repairing effects includes polydeoxyribonucleotides, fibronectin, and serum proteins. In the composition of this invention, polydeoxyribonucleotides can rapidly activate cell activity, while fibronectin and serum proteins, as core nutrients, can quickly enter the skin using the already repaired skin's metabolic capacity. The combination of these three components has a synergistic effect, which can significantly improve the skin's wrinkle-reducing and repairing effects.

A thermally responsive nanosphere for binding to biofilms including a gold nanoparticle core functionalized with a polyethylene glycol; an R2ab fusion protein construct including an anchor that is a stable globular domain having a surface accessible cysteine residue, a linker, an S. epidermidis R2ab protein of SEQ ID NO. 1, and an elastin-like polypeptide. The linker may be a protein having SEQ ID NO. 7; and the anchor may be a modified third IgG binding domain from streptococcal protein G (GB3) having SEQ ID NO. 3, a ubiquitin protein having SEQ ID NO. 4, a Pin1 WW domain having SEQ ID NO. 5, and a fibronectin protein domain 3FN3 having SEQ ID NO. 6. A method for treating a biofilm containing S. epidermidis bacteria by binding a plurality of the nanospheres to the biofilm and exposing the biofilm to laser irradiation.

The invention is directed to a composition of soluble placental ECM in storage solution and the methods of manufacture related thereto. The solubilized placental ECM solution is manufactured through a process of partitioning placental ECM from the placental tissue in a high acidic pH environment and performing an ultrafiltration step and diafiltration step through a tangential flow filtration system to increase the pH. The soluble placental ECM retains the native characteristics of placental ECM components and includes collagens (types I, III, V, VI, IX, and X), elastin, laminin, and fibronectin.